Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesStarpharma Holdings Ltd

Starpharma Holdings Ltd

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.445 AUD -0.01 ( 3.26%)
Last update at 2026-11-06T05:10:00Z
VOLUME
523642
Market Cap
222.14M

Momentum Score

…

Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development and commercialization of dendrimer technology for pharmaceutical, healthcare applications, life science, and other applications in Australia and internationally. The company offers VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis (BV) and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom coating. It also involved in the development of a dendrimer-enhanced product (DEP) delivery platform, consisting of DEP SN38 for the treatment of ovarian and colorectal cancer that is in Phase II clinical trial; DEP cabazitaxel for prostate and ovarian cancer treatment that is in Phase II clinical trial; and DEP docetaxel to treat pancreatic and other cancers that is in Phase II clinical trial. In addition, the company is developing DEP HER2 radiodiagnostic and DEP HER2 ADC to treat solid tumors; DEP technology for antibody-drug conjugates; and SPL7013 for vaginal gel, a treatment of bacterial vaginosis and prevention of recurrent BV, and an antiviral condom. It has a collaboration agreement with Medicxi to develop petalion therapeutics, a novel cancer therapy using Starpharma's dendrimer technology. Starpharma Holdings Limited was incorporated in 1997 and is based in Richmond, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.44
Low
0.46
High
52 Week Price Range
0.32
Low
0.88
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Starpharma Holdings is an Australian biotech that develops and commercializes dendrimer-based products, notably an antimicrobial formulation (VivaGel) and a dendrimer-enabled drug-delivery platform (DEP) for partner and internal programs. Long-term growth may be driven by expanding product sales, licensing and royalty income from DEP collaborations, and deployment of the platform across additional indications, which could support diversified revenue streams.

Material risks include clinical and regulatory setbacks, dependence on a limited product and partner base, competitive pressure in infectious disease and drug delivery, and the need for ongoing funding.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.46
Dividend Yield
-
Revenue TTM
12.67M
Revenue Per Share
0.03
Gross Profit TTM
0.77M
Debt / Equity
0.05
ROE
-45.55%
Net Debt
-10.31M
ROCE
-138.85%
Diluted EPS TTM
-0.02

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Income before tax -18.61M -9.99M -13.69M -15.64M -16.15M
Net income -7.46M -9.99M -8.16M -15.64M -16.15M
Selling general administrative - 3.03M 3.57M 3.77M 3.29M
Selling and marketing expenses - 3.23M 3.66M - -
Gross profit 10.39M 3.69M 7.66M 1.82M 1.91M
Reconciled depreciation - 1.07M 1.11M 1.19M 1.08M
Ebit -19.23M -12.00M -10.75M -18.24M -17.71M
Ebitda -18.32M -10.93M -9.63M -17.04M -16.63M
Depreciation and amortization 0.91M 1.07M 1.11M 1.19M 1.08M
Operating income -19.23M -12.00M -15.16M -15.77M -16.15M
Other operating expenses 31.28M 16.91M 23.45M 19.85M 21.32M
Interest expense - - - - 0.22M
Tax provision - 0.00M 0.00M 0.00M 0.00M
Interest income - 0.94M 1.47M 1.27M 0.22M
Net interest income - 0.94M 1.47M 1.27M 0.22M
Income tax expense -11.15M -8.36M -5.53M -2.46M -1.29M
Total revenue 12.05M 4.91M 8.29M 2.94M 4.68M
Total operating expenses 29.63M 15.69M 22.82M 20.05M 19.62M
Cost of revenue 1.66M 1.22M 0.63M 1.12M 2.78M
Total other income expense net 0.62M 2.01M 1.47M 0.14M 0.26M
Net income from continuing ops - -9.99M -8.16M -15.64M -16.15M
Net income applicable to common shares - -9.99M -8.16M -15.64M -16.15M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total assets 19.02M 25.42M 36.81M 52.09M 66.17M
Other current assets 0.52M - 0.81M 0.93M 0.08M
Total liab 5.24M 6.42M 8.70M 17.27M 17.78M
Total stockholder equity 13.78M 19.00M 28.12M 34.81M 48.39M
Other current liab 2.22M - 2.34M 2.33M 2.31M
Common stock 240.75M - 240.75M 240.72M 240.67M
Capital stock - 240.75M - 240.72M 240.67M
Retained earnings -259.82M -252.35M -242.36M -234.20M -218.56M
Other liab - - - 0.05M 0.06M
Other assets - - 0.00M - -
Cash 11.02M 15.41M 23.36M 35.18M 49.92M
Cash and equivalents - - - 33.52M 45.79M
Total current liabilities 5.17M 5.23M 6.66M 14.47M 10.23M
Current deferred revenue 0.11M - 0.03M 0.00M 0.47M
Net debt -10.31M - -19.83M -26.91M -41.73M
Short term debt 0.71M - 1.57M 5.52M 0.69M
Short long term debt - 0.44M - 4.78M -
Short long term debt total 0.71M - 3.53M 8.27M 8.19M
Other stockholder equity - - - -6.52M -22.11M
Property plant equipment - - - 4.96M 5.52M
Total current assets 17.58M 22.56M 32.92M 47.12M 60.66M
Net tangible assets - - - 34.81M 48.39M
Net receivables 4.39M 4.04M 6.34M 8.23M 7.84M
Long term debt - - - 0.00M 4.00M
Inventory 1.66M 1.92M 2.41M 2.77M 2.82M
Accounts payable 2.14M 2.05M 2.73M 6.62M 6.76M
Accumulated other comprehensive income 32.84M - 29.73M 28.30M 26.29M
Non currrent assets other - - - -4.96M -5.52M
Non current assets total 1.44M 2.86M 3.90M 4.96M 5.52M
Capital lease obligations - 1.96M - 3.49M 4.19M
Long term debt total - - - 2.75M 7.49M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Investments - -0.04M -0.09M -0.61M -0.84M
Change to liabilities - - - -0.55M 0.34M
Total cashflows from investing activities -0.26M -0.04M -0.09M -0.61M -0.84M
Net borrowings - -0.33M -4.00M -0.69M 3.23M
Total cash from financing activities -0.88M -1.13M -4.75M -0.69M 3.23M
Change to operating activities - - - 0.71M -0.01M
Net income -7.46M -9.99M -8.16M -15.64M -16.15M
Change in cash -4.39M -7.95M -11.82M -14.74M -10.58M
Begin period cash flow 15.41M 23.36M 35.18M 49.92M 60.50M
End period cash flow 11.02M 15.41M 23.36M 35.18M 49.92M
Total cash from operating activities -3.21M -6.76M -6.98M -13.53M -13.16M
Depreciation 0.91M - 1.11M 1.19M 1.08M
Other cashflows from investing activities - - 0.00M 0.01M 0.00M
Change to inventory 0.26M 0.49M 0.36M 0.05M -1.10M
Change to account receivables 0.33M 1.86M 2.06M -1.26M 0.63M
Sale purchase of stock - - - - 0.00M
Other cashflows from financing activities -0.80M -0.80M -0.74M -0.78M -0.77M
Change to netincome - - - 1.95M 2.05M
Capital expenditures 0.29M 0.04M 0.09M 0.62M 0.84M
Change in working capital 1.07M 1.26M -1.40M -1.04M -0.14M
Stock based compensation - - 1.47M 2.06M 2.25M
Other non cash items 2.27M -8.02M 1.47M 5.63M 4.40M
Free cash flow -3.50M -6.80M -7.07M -14.15M -14.00M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
SPL
Starpharma Holdings Ltd		 -0.01
3.26%		 0.45 - 312.50 17.54 15.95 17.38 -9.49
CSL
CSL Ltd		 -0.36
0.18%		 202.04 - 22.57 6.15 4.48 4.82 10.06
TLX
TELIX Pharmaceuticals Ltd		 -0.41
2.91%		 13.67 93.87 166.67 5.37 6.37 3.85 47.29
NEU
Neuren Pharmaceuticals Ltd		 -
-%		 23.24 154.93 36.36 42.38 7.52 31.95 160.40
MSB
Mesoblast Ltd		 -0.14
6.45%		 2.03 - 454.55 23.43 3.36 18.28 -9.86

Profile*

Starpharma Holdings Ltd

Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development and commercialization of dendrimer technology for pharmaceutical, healthcare applications, life science, and other applications in Australia and internationally. The company offers VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis (BV) and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom coating. It also involved in the development of a dendrimer-enhanced product (DEP) delivery platform, consisting of DEP SN38 for the treatment of ovarian and colorectal cancer that is in Phase II clinical trial; DEP cabazitaxel for prostate and ovarian cancer treatment that is in Phase II clinical trial; and DEP docetaxel to treat pancreatic and other cancers that is in Phase II clinical trial. In addition, the company is developing DEP HER2 radiodiagnostic and DEP HER2 ADC to treat solid tumors; DEP technology for antibody-drug conjugates; and SPL7013 for vaginal gel, a treatment of bacterial vaginosis and prevention of recurrent BV, and an antiviral condom. It has a collaboration agreement with Medicxi to develop petalion therapeutics, a novel cancer therapy using Starpharma's dendrimer technology. Starpharma Holdings Limited was incorporated in 1997 and is based in Richmond, Australia.

Suite 3.02, Richmond, VIC, Australia, 3121

61 3 8532 2700

https://starpharma.com

50

Name Title Year Born
Dr. Jacinth K. Fairley B.Sc., B.V.Sc.(Hons), GAICD, MBA CEO, MD & Exec. Director 1963
Mr. Nigel J. Baade B.Com, Grad. Dip., CPA CFO & Company Sec. NA
Mr. Justin Cahill CFO & Company Secretary NA
Ms. Cheryl Maley B.Sc., M.B.A. CEO, MD & Director 1969
Mr. Justin Cahill CFO & Company Secretary NA
Ms. Cheryl Maley B.Sc., M.B.A. CEO, MD & Director 1969
Mr. Justin Cahill CFO & Company Secretary NA
Ms. Cheryl Maley B.Sc., M.B.A. CEO, MD & Director 1969
Mr. Justin Cahill CFO & Company Secretary NA
Ms. Cheryl Maley B.Sc., M.B.A. CEO, MD & Director 1969

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…